Eli Lilly launched a program aimed at expanding employer coverage of GLP‑1 obesity medicines while new meta‑analysis data show weight regain after GLP‑1 receptor agonists tends to plateau below starting weight. Lilly’s offering gives employers an alternative route to subsidize employee access amid stalled insurer coverage. The company positioned the program as a way to broaden uptake for workplace‑insured populations. Separately, a meta‑analysis covering randomized and nonrandomized trials reported that weight regained after stopping GLP‑1 receptor agonists typically levels off at about 75.5% of the weight lost—meaning patients on average retain some net weight reduction compared with baseline. The study pooled 36 randomized controlled trials and 12 nonrandomized studies to quantify post‑treatment trajectories. Together, the commercial push and clinical durability data frame the evolving payer and clinical calculus for GLP‑1s: manufacturers are testing new access models while researchers quantify expected long‑term patient outcomes after treatment cessation. Employers, clinicians, and payers may use these findings to shape coverage decisions and expectations for maintenance strategies.